Y-Intercept (HK)’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.01M | Buy |
336,095
+194,230
| +137% | +$1.74M | 0.07% | 422 |
|
|
2025
Q1 | $1.06M | Buy |
141,865
+73,242
| +107% | +$549K | 0.07% | 384 |
|
|
2024
Q4 | $516K | Sell |
68,623
-14,500
| -17% | -$109K | 0.03% | 707 |
|
|
2024
Q3 | $632K | Sell |
83,123
-6,229
| -7% | -$47.3K | 0.04% | 660 |
|
|
2024
Q2 | $552K | Buy |
+89,352
| New | +$552K | 0.03% | 767 |
|
|
2022
Q4 | – | Sell |
-29,226
| Closed | -$368K | – | 1003 |
|
|
2022
Q3 | $368K | Buy |
+29,226
| New | +$368K | 0.04% | 637 |
|
|
2022
Q1 | – | Sell |
-11,042
| Closed | -$153K | – | 721 |
|
|
2021
Q4 | $153K | Buy |
+11,042
| New | +$153K | 0.04% | 527 |
|
|
2021
Q3 | – | Sell |
-10,737
| Closed | -$170K | – | 649 |
|
|
2021
Q2 | $170K | Buy |
+10,737
| New | +$170K | 0.04% | 544 |
|
|
2021
Q1 | – | Sell |
-12,579
| Closed | -$94K | – | 625 |
|
|
2020
Q4 | $94K | Buy |
+12,579
| New | +$94K | 0.04% | 482 |
|